BackImmunoPrecise Antibodies Overview

ImmunoPrecise Antibodies Receivables

Track ImmunoPrecise Antibodies's receivables ($3M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$3.03M
↓ 37.67% YoYΔ $-1.83M vs prior year quarter

Peer trimmed avg / median

Loading

ImmunoPrecise Antibodies Receivables History

Loading

ImmunoPrecise Antibodies vs. peers: Receivables Comparison

Loading

ImmunoPrecise Antibodies Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ImmunoPrecise Antibodies (IPA) FAQ

ImmunoPrecise Antibodies (IPA) currently reports a receivables of $3M as of January 2026. That compares with $4.9M in the prior-year period — down 37.7% year over year. Use the charts on this page to explore ImmunoPrecise Antibodies's receivables history and peer comparisons.

ImmunoPrecise Antibodies's receivables decreased from $4.9M to $3M — a 37.7% year-over-year decrease (period ending January 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunoPrecise Antibodies reported $3M in receivables as of January 2026. That compares with $4.9M in the prior-year period — down 37.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ImmunoPrecise Antibodies, and consider following IPA for alerts when major investors trade the stock.

ImmunoPrecise Antibodies is classified in the Healthcare sector. On receivables, it currently shows $3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IPA with unrelated industries.